lenacapavir

Gilead Sciences reports positive data from HIV therapy trial
Gilead Sciences reports positive data from HIV therapy trial
Clinical Trials Arena
Gilead Sciences
lenacapavir
HIV
clinical trials
Flag link:
Gilead goes long-acting in HIV
Gilead goes long-acting in HIV
EP Vantage
Gilead Sciences
lenacapavir
HIV
FDA
Flag link:
4 Biotech Stocks With Huge Incoming Catalysts
4 Biotech Stocks With Huge Incoming Catalysts
Motley Fool
FDA
Biogen
Eisai
Alzheimer's disease
Gilead Sciences
HIV
Mirati Therapeutics
lung cancer
lecanemab
lenacapavir
adagrasib
Flag link:
Gilead tries again with twice-yearly HIV drug lenacapavir
Gilead tries again with twice-yearly HIV drug lenacapavir
Pharmaforum
Gilead Sciences
HIV
FDA
lenacapavir
Flag link:
Gilead HIV prospect escapes FDA hold after glass compatibility glitch triggered regulatory setbacks
Gilead HIV prospect escapes FDA hold after glass compatibility glitch triggered regulatory setbacks
Fierce Pharma
Gilead Sciences
drug manufacturing
FDA
HIV
lenacapavir
Flag link:
FDA rejects Gilead's closely watched HIV drug
FDA rejects Gilead's closely watched HIV drug
BioPharma Dive
Gilead Sciences
HIV
FDA
lenacapavir
Flag link:
FDA slaps a hold on Gilead's injectable HIV treatment over concerns about potential glass contaminants
FDA slaps a hold on Gilead's injectable HIV treatment over concerns about potential glass contaminants
Endpoints
Gilead Sciences
FDA
HIV
lenacapavir
clinical trials
clinical hold
Flag link:
Gilead cements its long-acting HIV ambitions
Gilead cements its long-acting HIV ambitions
EP Vantage
Gilead Sciences
HIV
lenacapavir
clinical trials
Flag link:
Gilead challenges ViiV in resistant HIV, filing twice-yearly therapy
Gilead challenges ViiV in resistant HIV, filing twice-yearly therapy
Pharmaforum
Gilead Sciences
HIV
ViiV Healthcare
FDA
lenacapavir
Rukobia
Flag link:
Data sets up 2021 filings for Gilead’s twice-a-year HIV drug lenacapavir
Data sets up 2021 filings for Gilead’s twice-a-year HIV drug lenacapavir
Pharmaforum
Gilead Sciences
lenacapavir
HIV
Flag link:
New Data Shows Promise Involving Lenacapavir for the Treatment of HIV
New Data Shows Promise Involving Lenacapavir for the Treatment of HIV
BioSpace
Gilead Sciences
lenacapavir
HIV
Flag link:
Experimental HIV drug seems effective at a twice-a-year dose, study finds
Experimental HIV drug seems effective at a twice-a-year dose, study finds
Stat
HIV
Gilead Sciences
lenacapavir
clinical trials
Flag link: